Xenetic Biosciences, Inc. (XBIO) Rating Lowered to Hold at Zacks Investment Research
Xenetic Biosciences, Inc. (NASDAQ:XBIO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “
Shares of Xenetic Biosciences (XBIO) traded up 3.27% during trading on Wednesday, reaching $2.21. The company’s stock had a trading volume of 15,785 shares. The company has a 50 day moving average price of $2.60 and a 200 day moving average price of $2.59. The firm’s market capitalization is $19.26 million. Xenetic Biosciences has a 52 week low of $1.75 and a 52 week high of $5.90.
Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Monday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.13). On average, equities research analysts expect that Xenetic Biosciences will post ($0.89) EPS for the current fiscal year.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.